Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
Our Identity Crisis
I recently embarked on a quest to determine who we are and what we do as hematologists. I figured it couldn’t be that hard, getting...
Demystifying Proteomics in Hematology
The central dogma of molecular biology describes the flow of information in a cell, from the DNA in a gene to RNA to protein....
Pregnancy History and Sex of Red Cell Donors Does Not Increase Mortality Risk for...
Previous research has suggested that receipt of a red blood cell (RBC) transfusion from a female donor who has ever been pregnant increases mortality...
CMS Expands Access to CAR T-Cell Therapies Nationwide
The Centers for Medicare and Medicaid Services (CMS) will now provide “consistent and predictable” nationwide access to chimeric antigen receptor (CAR) T-cell therapies, according...
Doctors Rally to Support Disabled Indian Medical School Applicants in Legal Case
Doctors and medical groups from the U.S., U.K., and Australia expressed their opposition to a recent decision from the Medical Council of India (MCI)...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
